Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

Inclusion Criteria: * Documented HIV-1 infection by means of any one of the following: Documentation of HIV diagnosis in the medical record by a licensed health care provider; OR HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL; OR any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid Multispot antibody differentiation assay. * On an Integrase Strand Transfer Inhibitor (INSTI) based regimen for at least 1 year and less than 5 years prior to screening * Significant weight gain since initiation of the INSTI-based regimen (\>10% of baseline body weight) * Viral load of \<200 copies/mL for \> 6 consecutive months prior to screening (single viral blips \<200 copies/mL accepted if re-suppressed) * Documentation of weight, glycemia, cholesterol, and blood pressure (BP) history within the last year. * Signed Informed Consent Form (Appendix B) and willing to comply with the protocol. * Using proper contraception if of child bearing age and potential. Exclusion Criteria: * Pregnancy or desire to become pregnant within the next year * Failure to use adequate contraception during the study if of child-bearing potential. * Any underlying documented ART resistance to doravirine, tenofovir disoproxil fumarate, or lamivudine * Prior virologic failure * Concomitant drugs that interact with doravirine * Initiated on concomitant dru…